These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 26478544)

  • 21. Which drug should we use for stroke prevention in atrial fibrillation?
    Lau YC; Lip GY
    Curr Opin Cardiol; 2014 Jul; 29(4):293-300. PubMed ID: 25029448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. New anticoagulants for atrial fibrillation.
    De Caterina R; Kristensen SD; Renda G
    J Cardiovasc Med (Hagerstown); 2009 Jun; 10(6):446-53. PubMed ID: 19365276
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Help prevent Afib-related stroke. New anticoagulants for atrial fibrillation prove as effective, or even better than, warfarin--and easier to use.
    Duke Med Health News; 2014 Sep; 20(9):3. PubMed ID: 25358137
    [No Abstract]   [Full Text] [Related]  

  • 24. Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF).
    Washam JB; Stevens SR; Lokhnygina Y; Halperin JL; Breithardt G; Singer DE; Mahaffey KW; Hankey GJ; Berkowitz SD; Nessel CC; Fox KA; Califf RM; Piccini JP; Patel MR;
    Lancet; 2015 Jun; 385(9985):2363-70. PubMed ID: 25749644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Future directions of stroke prevention in atrial fibrillation: the potential impact of novel anticoagulants and stroke risk stratification.
    Cabral KP; Ansell J; Hylek EM
    J Thromb Haemost; 2011 Mar; 9(3):441-9. PubMed ID: 21176102
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antithrombotics in atrial fibrillation and coronary disease.
    Velagapudi P; Turagam MK; Agrawal H; Mittal M; Kocheril AG; Aggarwal K
    Expert Rev Cardiovasc Ther; 2014 Aug; 12(8):977-86. PubMed ID: 25046150
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Transition from apixaban to warfarin--addressing excess stroke, systemic embolism, and major bleeding.
    Cairns JA; Weitz JI
    Am Heart J; 2015 Jan; 169(1):1-3. PubMed ID: 25497240
    [No Abstract]   [Full Text] [Related]  

  • 28. Non-vitamin K antagonist oral anticoagulants in atrial fibrillation and venous thromboembolism: where are we now?
    Hajhosseiny R; Sabir I; Lip GY
    Hosp Pract (1995); 2014 Oct; 42(4):153-62. PubMed ID: 25502139
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Not Available].
    Christersson C
    Lakartidningen; 2018 Dec; 115():. PubMed ID: 30512141
    [No Abstract]   [Full Text] [Related]  

  • 30. Warfarin for stroke prevention in atrial fibrillation: time to switch?
    Ahmad Y; Lip GY
    Int J Clin Pract; 2013 Jul; 67(7):603-5. PubMed ID: 23758442
    [No Abstract]   [Full Text] [Related]  

  • 31. Comparative efficacy and safety of the non-vitamin K antagonist oral anticoagulants for patients with nonvalvular atrial fibrillation.
    Senoo K; Lip GY
    Semin Thromb Hemost; 2015 Mar; 41(2):146-53. PubMed ID: 25682085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Should dabigatran or vitamin K antagonists be used in prevention of stroke in patients with atrial fibrillation?].
    Calvo Romero JM
    Rev Clin Esp; 2011 Mar; 211(3):142-6. PubMed ID: 21371701
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rivaroxaban versus warfarin or dabigatran in patients undergoing catheter ablation for atrial fibrillation: A meta-analysis.
    Phan K; Wang N; Pison L; Kumar N; Hitos K; Thomas SP
    Int J Cardiol; 2015 Apr; 185():209-13. PubMed ID: 25797679
    [No Abstract]   [Full Text] [Related]  

  • 34. [New concepts of anticoagulant therapy of atrial fibrillation].
    Guedon-Moreau L; Brigadeau F; Kacet S
    Arch Mal Coeur Vaiss; 2004 Nov; 97(11):1058-62. PubMed ID: 15609907
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anticoagulant agents.
    J Assoc Physicians India; 2014 Jun; 62(6 Suppl):10-8. PubMed ID: 25845123
    [No Abstract]   [Full Text] [Related]  

  • 37. Bridging therapy in oral anticoagulated patients: focusing on how to do it.
    Palareti G
    Intern Emerg Med; 2007 Dec; 2(4):247-9. PubMed ID: 18172591
    [No Abstract]   [Full Text] [Related]  

  • 38. [New anticoagulants: better knowledge, better prescriptions].
    Boehlen F; de Moerloose P
    Rev Med Suisse; 2012 Jan; 8(324):96-9. PubMed ID: 23185817
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [New options in the treatment of atrial fibrillation].
    Völler H
    Dtsch Med Wochenschr; 2013 Dec; 138(50):2579. PubMed ID: 24301489
    [No Abstract]   [Full Text] [Related]  

  • 40. Pathophysiology and pharmacologic treatment of venous thromboembolism.
    Bain J; Oyler DR; Smyth SS; Macaulay TE
    Curr Drug Targets; 2014 Feb; 15(2):199-209. PubMed ID: 24102472
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.